Upstream Bio Inc. (UPB)
7.41
-0.52 (-6.56%)
At close: Mar 03, 2025, 3:59 PM
7.90
6.68%
After-hours: Mar 03, 2025, 06:14 PM EST
Company Description
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Upstream Bio Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Dr. E. Rand Sutherland M.D., M.P.H., MPH |
Contact Details
Address: 890 Winter Street Waltham, Massachusetts United States | |
| Website | https://upstreambio.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US91678A1079 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. E. Rand Sutherland M.D., M.P.H., MPH | Chief Executive Officer & Director |
| Michael Paul Gray CPA, MBA | Chief Financial Officer & Chief Operating Officer |
| Aaron Deykin M.D. | Chief Medical Officer and Head of Research & Development |
| Allison Ambrose | General Counsel |
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer |
| Dr. Sumathi Sivapalasingam M.D. | Vice President & Head of Clinical Development |
| Fang Xie Ph.D. | Vice President & Head of Biometrics |
| Lisa Fiering | Senior Vice President of People & Culture |
| Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs & Quality |
| Parika Petaipimol M.S. | Head of Technical Operations |